Selected research
Industry Growth & Trends
Global Antibody-drug Conjugate for Cancer Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Antibody-drug Conjugate for Cancer market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Antibody-drug Conjugate for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Antibody-drug Conjugate for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Antibody-drug Conjugate for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Antibody-drug Conjugate for Cancer market include Gilead Sciences, Innate Pharma, Rakuten Medical, Seagen, AstraZeneca, GSK, Pfizer, Roche and Takeda, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Antibody-drug Conjugate for Cancer market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Antibody-drug Conjugate for Cancer market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Antibody-drug Conjugate for Cancer market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Antibody-drug Conjugate for Cancer.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Antibody-drug Conjugate for Cancer market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Antibody-drug Conjugate for Cancer Market by Company
Gilead Sciences
Innate Pharma
Rakuten Medical
Seagen
AstraZeneca
GSK
Pfizer
Roche
Takeda
Antibody-drug Conjugate for Cancer Segment by Type
Hematological Malignancies Drugs
Solid Tumor Drugs
Antibody-drug Conjugate for Cancer Segment by Application
Hospital
Pharmacy
Other
Antibody-drug Conjugate for Cancer Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antibody-drug Conjugate for Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Antibody-drug Conjugate for Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antibody-drug Conjugate for Cancer.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Antibody-drug Conjugate for Cancer companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Hematological Malignancies Drugs
- Solid Tumor Drugs
Applications
- Hospital
- Pharmacy
- Other
Companies covered
- Gilead Sciences
- Innate Pharma
- Rakuten Medical
- Seagen
- AstraZeneca
- GSK
- Pfizer
- Roche
- Takeda
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Antibody-drug Conjugate for Cancer Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Antibody-drug Conjugate for Cancer Market Size by Region (2021-2032)
- 1.4.1 Global Antibody-drug Conjugate for Cancer Market Size by Region (2021-2026)
- 1.4.2 Global Antibody-drug Conjugate for Cancer Market Size by Region (2027-2032)
- 1.5 Key Regions Antibody-drug Conjugate for Cancer Market Size (2021-2032)
- 1.5.1 North America Antibody-drug Conjugate for Cancer Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Antibody-drug Conjugate for Cancer Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Antibody-drug Conjugate for Cancer Market Size Growth Rate (2021-2032)
- 1.5.4 South America Antibody-drug Conjugate for Cancer Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Antibody-drug Conjugate for Cancer Market Size Growth Rate (2021-2032)
2 Antibody-drug Conjugate for Cancer Market by Type
- 2.1 Type Introduction
- 2.1.1 Hematological Malignancies Drugs
- 2.1.2 Solid Tumor Drugs
- 2.2 Global Antibody-drug Conjugate for Cancer Market Size by Type
- 2.2.1 Global Antibody-drug Conjugate for Cancer Market Size Overview by Type (2021-2032)
- 2.2.2 Global Antibody-drug Conjugate for Cancer Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Antibody-drug Conjugate for Cancer Market Size Forecasted by Type (2027-2032)
- 2.3 Global Antibody-drug Conjugate for Cancer Market Size by Regions
- 2.3.1 North America Antibody-drug Conjugate for Cancer Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Antibody-drug Conjugate for Cancer Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Antibody-drug Conjugate for Cancer Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Antibody-drug Conjugate for Cancer Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Antibody-drug Conjugate for Cancer Market Size Breakdown by Type (2021-2026)
3 Antibody-drug Conjugate for Cancer Market by Application
- 3.1 Type Introduction
- 3.1.1 Hospital
- 3.1.2 Pharmacy
- 3.1.3 Other
- 3.2 Global Antibody-drug Conjugate for Cancer Market Size by Application
- 3.2.1 Global Antibody-drug Conjugate for Cancer Market Size Overview by Application (2021-2032)
- 3.2.2 Global Antibody-drug Conjugate for Cancer Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Antibody-drug Conjugate for Cancer Market Size Forecasted by Application (2027-2032)
- 3.3 Global Antibody-drug Conjugate for Cancer Market Size by Regions
- 3.3.1 North America Antibody-drug Conjugate for Cancer Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Antibody-drug Conjugate for Cancer Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Antibody-drug Conjugate for Cancer Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Antibody-drug Conjugate for Cancer Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Antibody-drug Conjugate for Cancer Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Antibody-drug Conjugate for Cancer Industry Trends
- 4.2 Antibody-drug Conjugate for Cancer Industry Drivers
- 4.3 Antibody-drug Conjugate for Cancer Industry Opportunities and Challenges
- 4.4 Antibody-drug Conjugate for Cancer Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Antibody-drug Conjugate for Cancer Revenue (2021-2026)
- 5.2 Global Antibody-drug Conjugate for Cancer Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Antibody-drug Conjugate for Cancer Key Company Headquarters & Area Served
- 5.4 Global Antibody-drug Conjugate for Cancer Company, Product Type & Application
- 5.5 Global Antibody-drug Conjugate for Cancer Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Antibody-drug Conjugate for Cancer Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Antibody-drug Conjugate for Cancer Players Market Share by Revenue in 2025
- 5.6.3 2025 Antibody-drug Conjugate for Cancer Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Gilead Sciences
- 6.1.1 Gilead Sciences Company Information
- 6.1.2 Gilead Sciences Business Overview
- 6.1.3 Gilead Sciences Antibody-drug Conjugate for Cancer Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Gilead Sciences Antibody-drug Conjugate for Cancer Product Portfolio
- 6.1.5 Gilead Sciences Recent Developments
- 6.2 Innate Pharma
- 6.2.1 Innate Pharma Company Information
- 6.2.2 Innate Pharma Business Overview
- 6.2.3 Innate Pharma Antibody-drug Conjugate for Cancer Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Innate Pharma Antibody-drug Conjugate for Cancer Product Portfolio
- 6.2.5 Innate Pharma Recent Developments
- 6.3 Rakuten Medical
- 6.3.1 Rakuten Medical Company Information
- 6.3.2 Rakuten Medical Business Overview
- 6.3.3 Rakuten Medical Antibody-drug Conjugate for Cancer Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Rakuten Medical Antibody-drug Conjugate for Cancer Product Portfolio
- 6.3.5 Rakuten Medical Recent Developments
- 6.4 Seagen
- 6.4.1 Seagen Company Information
- 6.4.2 Seagen Business Overview
- 6.4.3 Seagen Antibody-drug Conjugate for Cancer Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Seagen Antibody-drug Conjugate for Cancer Product Portfolio
- 6.4.5 Seagen Recent Developments
- 6.5 AstraZeneca
- 6.5.1 AstraZeneca Company Information
- 6.5.2 AstraZeneca Business Overview
- 6.5.3 AstraZeneca Antibody-drug Conjugate for Cancer Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 AstraZeneca Antibody-drug Conjugate for Cancer Product Portfolio
- 6.5.5 AstraZeneca Recent Developments
- 6.6 GSK
- 6.6.1 GSK Company Information
- 6.6.2 GSK Business Overview
- 6.6.3 GSK Antibody-drug Conjugate for Cancer Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 GSK Antibody-drug Conjugate for Cancer Product Portfolio
- 6.6.5 GSK Recent Developments
- 6.7 Pfizer
- 6.7.1 Pfizer Company Information
- 6.7.2 Pfizer Business Overview
- 6.7.3 Pfizer Antibody-drug Conjugate for Cancer Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Pfizer Antibody-drug Conjugate for Cancer Product Portfolio
- 6.7.5 Pfizer Recent Developments
- 6.8 Roche
- 6.8.1 Roche Company Information
- 6.8.2 Roche Business Overview
- 6.8.3 Roche Antibody-drug Conjugate for Cancer Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Roche Antibody-drug Conjugate for Cancer Product Portfolio
- 6.8.5 Roche Recent Developments
- 6.9 Takeda
- 6.9.1 Takeda Company Information
- 6.9.2 Takeda Business Overview
- 6.9.3 Takeda Antibody-drug Conjugate for Cancer Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Takeda Antibody-drug Conjugate for Cancer Product Portfolio
- 6.9.5 Takeda Recent Developments
7 North America
- 7.1 North America Antibody-drug Conjugate for Cancer Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Antibody-drug Conjugate for Cancer Market Size by Country (2021-2026)
- 7.3 North America Antibody-drug Conjugate for Cancer Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Antibody-drug Conjugate for Cancer Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Antibody-drug Conjugate for Cancer Market Size by Country (2021-2026)
- 8.3 Europe Antibody-drug Conjugate for Cancer Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Antibody-drug Conjugate for Cancer Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Antibody-drug Conjugate for Cancer Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Antibody-drug Conjugate for Cancer Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Antibody-drug Conjugate for Cancer Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Antibody-drug Conjugate for Cancer Market Size by Country (2021-2026)
- 10.3 South America Antibody-drug Conjugate for Cancer Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Antibody-drug Conjugate for Cancer Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Antibody-drug Conjugate for Cancer Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Antibody-drug Conjugate for Cancer Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst